Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): A short, safe, and effective postoperative regimen for high-risk breast cancer patients

International Journal of Radiation Oncology Biology Physics

Volumn 52, Issue 1, 2002, Pages 144-155

  Koukourakis, Michael I ^a,c   Giatromanolaki, Alexandra ^a   Kouroussis, Charalambos ^b   Kakolyris, Stelios ^b   Sivridis, Efthimios ^a   Frangiadaki, Chryssi ^b   Retalis, George ^a   Georgoulias, Vassilis ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c Tumour and Angiogenesis Research Group Iraklion   (Greece)

Author keywords

Acceleration; Alkaline phosphatase; Amifostine; Breast cancer; Hypofractionation; Radiotherapy

Indexed keywords

DISEASES; PATIENT TREATMENT; SURGERY; TOXICITY; TUMORS;

BREAST CANCER;

RADIOTHERAPY;

ALKALINE PHOSPHATASE; AMIFOSTINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TROPISETRON;

ADULT; AGED; ARTICLE; ASTHENIA; BREAST CANCER; CELL PROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FEVER; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION PNEUMONIA; RADIOBIOLOGY; RADIOTHERAPY; RASH; RECURRENCE RISK; SAFETY; SKIN TOXICITY; SURVIVAL RATE; TECHNIQUE; TREATMENT OUTCOME;

ADULT; AGED; ALKALINE PHOSPHATASE; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOSE FRACTIONATION; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY; MASTECTOMY, MODIFIED RADICAL; MIDDLE AGED; NAUSEA; RADIATION PNEUMONITIS; RADIATION-PROTECTIVE AGENTS; RADIOBIOLOGY; RADIODERMATITIS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; VOMITING;

EID: 0036137527     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01759-X     Document Type: Article

References (32)

1. Randomised controlled trial of conservation therapy for breast cancer; 6-year analysis of the Scottish trial Scottish Cancer Trials Breast Group
2. Effects of radiotherapy and surgery in early breast cancer; An overview of the randomized trials
3. The role of radiotherapy in patients receiving adjuvant chemotherapy after mastectomy; Results of a randomized trial
4. Radiotherapy related adjuvant chemotherapy initiation delay in breast cancer with positive nodes; Does it affect prognosis? A South-eastern Cancer Study group report
5. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer; An update. Ontario Clinical Oncology Group
6. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy
7. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen; Danish Breast Cancer Cooperative Group DBCG 82c randomised trial
8. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
9. Postmastectomy radiation; Back to center stage?
10. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation; Experience of the Eastern Cooperative Oncology Group
11. Breast cancer
12. Sector resection with or without postoperative radiotherapy for stage I breast cancer; Five-year results of a randomized trial. Uppsala-Orebro Breast Cancer Study Group
13. Hypofractionated and accelerated radiotherapy with Ethyol cytoprotection (HypoARC) for locally advanced breast cancer
14. A new isoeffect curve for change in dose per fraction
15. The impact of overall treatment time on the results of radiotherapy for non-small cell lung cancer
16. The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy
17. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer
18. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx; Tumor dose-response and repopulation
19. Comparative evaluation of angiogenesis assessment with anti-Factor VIII and anti-CD31 immunostaining in non small cell lung cancer
20. Radiotherapy-related lung fibrosis enhanced by tamoxifen
21. Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer
22. Breast conservation; Long-term results from Westmead Hospital
23. Adjuvant chest wall and nodal irradiation; Maximize cure, minimize late cardiac toxicity
24. No serious late cardiac effects after adjuvant radiotherapy following mastectomy in premenopausal women with early breast cancer
25. Subcutaneous administration of amifostine during fractionated radiotherapy. A randomized phase II study
26. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery
27. Use of radiation with or without WR-2721 in advanced rectal cancer
28. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer
29. A liquid chromatographic electrochemical assay for S-2-(3-aminopropylamino) ethylphosphorothioate (WR2721) in human plasma
30. Active versus passive absorption kinetics as the basis for selective protection of normal tissue by S-2-(3-Aminopropylamino)-ethylphosphorothioic acid